Key Stats for Scholar Rock Stock
- Stock Movement (Recent): +7.04%
- Current Price: $47.43
- Street Target Price: $53.79
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Scholar Rock Holding Corporation (SRRK) is navigating a pivotal transition phase, with shares surging 7.04% to $47.43 following a highly optimistic fourth-quarter 2025 earnings call that detailed its robust commercial readiness.
Operating expenses for the quarter were $91.9 million, which included $19.4 million in noncash stock-based compensation.
The most significant financial update came from the balance sheet. Scholar Rock ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from recently exercised warrants.
Furthermore, the company announced a massive new capital injection to fund its upcoming launch.
CFO Vikas Sinha stated verbatim: “We continue to strengthen our balance sheet and are pleased to announce today that we secured a new debt facility for up to $550 million with Blue Owl Capital.”
Operationally, CEO David Hallal provided a highly anticipated update regarding the FDA’s review of apitegromab, the company’s lead muscle-targeted therapy for SMA.
Following a warning letter issued to Catalent Indiana (the third-party manufacturer), Novo Nordisk assumed remediation efforts.
Hallal noted that the FDA recently sent a field team to the site and had no additional requests for the remediation plan.
As a result, Scholar Rock reaffirmed its guidance to resubmit its Biologics License Application (BLA) and launch apitegromab in the U.S. in 2026.
See analysts’ growth forecasts and price targets for Scholar Rock stock (It’s free!) >>>
Is Scholar Rock Undervalued Today?
Aggregated analyst data indicate that the broader market is undervaluing the scale of the unpenetrated muscle-targeted SMA market, which apitegromab is uniquely positioned to capture.
The consensus Street target price of $53.79 represents an attractive 13.41% potential return from the current $47.43 baseline.
While navigating third-party manufacturing delays, the operational reality shows a company heavily capitalized and structurally ready to disrupt a $5 billion global SMA market.
Chief Operating Officer Keith Woods explained exactly why the current standard of care is insufficient and why apitegromab is primed for high demand.
Woods stated verbatim: “While SMN-targeted therapies have brought much needed innovation, muscle strength and motor function remain the top unmet need with 95% of patients continuing to experience persistent and progressive muscle weakness.”
Read the full Scholar Rock Transcript on TIKR to see the 2026 clinical pipeline >>>
Valuation Deep Dive
The TIKR Analyst Breakdown identifies Scholar Rock as a highly specialized biotech leader successfully leveraging its proprietary anti-myostatin platform to target severe neuromuscular diseases.
- Street Target Price: $53.79
- Current Price: $47.43
- Target Return: 13.41%
The Commercial Launch Engine: Scholar Rock is aggressively positioning itself for day-one commercial execution. The company has already established a home infusion network of more than 10,000 affiliated nurses nationwide and expanded its specialty pharmacy network to ensure seamless access for patients already receiving standard SMN-targeted therapies. Simultaneously, the company is preparing for a European launch in the second half of 2026, beginning in Germany, pending a mid-year decision from the European Medicines Agency (EMA).
Explosive Pipeline Expansion: Beyond its lead asset, the company’s R&D engine is operating at full throttle. Scholar Rock cleared its IND for apitegromab in facioscapulohumeral muscular dystrophy (FSHD), a disease affecting 30,000 patients with zero approved therapies, and plans to initiate a 60-patient Phase II FORGE study by mid-2026. Furthermore, its next-generation myostatin inhibitor, SRK-439, which preclinical data suggest is 10 times more potent than apitegromab, expects top-line Phase I data in the second half of the year.
Conclusion: A heavily funded biotech pioneer successfully navigating the final regulatory hurdles before bringing a paradigm-shifting therapy to market. Scholar Rock offers a highly compelling, catalyst-driven path to long-term appreciation. The path forward is paved by the successful FDA reinspection of its manufacturing site, the impending BLA resubmission, and the continued clinical advancement of its broader anti-myostatin pipeline.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Scholar Rock?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Scholar Rock, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Scholar Rock alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
[Analyze Scholar Rock on TIKR Free →]
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
